Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
All content curated by

News · March 14, 2022

AAAAI 2022: Ligelizumab May Confer Chronic Spontaneous Urticaria Patients With Angioedema the Same Quality of Life as Those Without Angioedema

Benefits of this investigational drug do not appear to be influenced by levels of baseline basophil histamine release

PracticeUpdate Editorial Team

 

Further Reading